Company / Operating Income
IGC Pharma, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$7.4M
FY2025
5-year range
-$15.4M / -$6.9M
FY2021-FY2025
Trend
+35.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$15M to -$7M over the past 2 years.
Based on SEC 10-K filings.
-$7M in FY2025.
Improved from -$15M to -$7M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 35.6% year-over-year.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$7.4M | +35.6% |
| FY2024 | -$11.6M | +25.0% |
| FY2023 | -$15.4M | -76.8% |
| FY2022 | -$8.7M | -27.1% |
| FY2021 | -$6.9M | -47.8% |
| FY2020 | -$4.6M | -159.5% |
| FY2019 | -$1.8M | +12.9% |
| FY2018 | -$2.1M | +29.3% |
| FY2017 | -$2.9M | +33.1% |
| FY2016 | -$4.3M | -71.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026